Literature DB >> 27164963

Protective Effects of Chaihu Shugan San () on Nonalcoholic Fatty Liver Disease in Rats with Insulin Resistance.

Wei-Ning Jiang1, Dan Li1, Tao Jiang2, Jiao Guo3, Yan-Fen Chen1, Jie Wang1, Yun Zhou1, Chao-Yan Yang1, Chun-Ping Tang4.   

Abstract

OBJECTIVE: To investigate the protective effects of Chinese medicine formulation Chaihu Shugan San (, CHSGS) on nonalcoholic fatty liver disease (NAFLD) in rats with insulin resistance (IR) and its molecular mechanisms.
METHODS: Male Sprague-Dawley rats were randomly divided into six groups: the control group, the model group, Dongbao Gantai group (, DBGT, 0.09 g methionine/kg), CHSGS high-dose group (CHSG-H, 12.6 g crude drug/kg), CHSGS medium-dose group (CHSG-M, 6.3 g crude drug/kg), and CHSGS low-dose group (CHSG-L, 3.15 g crude drug/kg). After establishing the NAFLD rat model and treatment for 8 weeks, total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), free fatty acid (FFA), fasting blood glucose (FBG), fasting insulin (FINS) contents in blood serum, and TC, TG contents in the hepatic homogenate were measured by an automatic biochemical analyzer, and a homeostasis model assessment was applied to assess the status of IR, insulin sensitivity index (ISI), and homeostasis model assessment for insulin secretion (HOMA-IS). The expression levels of adiponectin and leptin mRNA in liver tissue were analyzed by reverse transcription polymerase chain reaction. Pathological changes of livers were observed by hematoxylin-eosin staining of paraffin section.
RESULTS: Compared with the model group, the serum levels of TC, TG, FFA, FBG, FINS, IRI, ISI, and the liver levels of TC and TG in CHSG-H, CHSG-M, CHSG-L groups showed significant declines (P<0.01 or P<0.05); the serum levels of HDL-C, HOMA-IS were significantly increased (P<0.01 or P<0.05); the expression of leptin mRNA was dramatically decreased and the expression of adiponectin mRNA was increased in the hepatic tissue (P<0.01 or P<0.05). The fatty deposition of liver cells could also be alleviated.
CONCLUSION: CHSGS could up-regulate the expression of adiponectin mRNA and down-regulate the expression of leptin mRNA on the liver, suggesting the CHSGS had positive therapeutic effect on NAFLD in rats with IR.

Entities:  

Keywords:  Chaihu Shugan San; Chinese medicine; adiponectin; insulin resistance; leptin; lipid metabolism; nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2016        PMID: 27164963     DOI: 10.1007/s11655-016-2252-4

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  19 in total

1.  [The role of improving insulin-resistant in the treatment and prevention of nonalcoholic fatty liver disease].

Authors:  Lun Gen Lu; Min De Zeng
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2003-02

Review 2.  Use and abuse of HOMA modeling.

Authors:  Tara M Wallace; Jonathan C Levy; David R Matthews
Journal:  Diabetes Care       Date:  2004-06       Impact factor: 19.112

3.  Apolipoprotein synthesis in nonalcoholic steatohepatitis.

Authors:  Michael Charlton; Raghavakaimal Sreekumar; Deborah Rasmussen; Keith Lindor; K Sreekumaran Nair
Journal:  Hepatology       Date:  2002-04       Impact factor: 17.425

Review 4.  Leptin: the prototypic adipocytokine and its role in NAFLD.

Authors:  Claudio Procaccini; Mario Galgani; Veronica De Rosa; Fortunata Carbone; Claudia La Rocca; Giusy Ranucci; Raffaele Iorio; Giuseppe Matarese
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

5.  Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling.

Authors:  Jörn M Schattenberg; Yongjun Wang; Rajat Singh; Raina M Rigoli; Mark J Czaja
Journal:  J Biol Chem       Date:  2005-01-04       Impact factor: 5.157

6.  [Effect of a compound Danshen preparation in preventing long-term gastric lipid emulsion administration-induced nonalcoholic steatohepatitis in rats].

Authors:  Zhi-ping Zhang; Ting-ting You; Li-yi Zou; Tie Wu; Yi Wu; Liao Cui
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2008-07

Review 7.  Molecular mechanisms involved in NAFLD progression.

Authors:  Mariano Malaguarnera; Michelino Di Rosa; Ferdinando Nicoletti; Lucia Malaguarnera
Journal:  J Mol Med (Berl)       Date:  2009-04-08       Impact factor: 4.599

8.  Serum leptin and soluble leptin receptor in non-alcoholic fatty liver disease.

Authors:  Xiao-Dong Huang; Yan Fan; Hen Zhang; Ping Wang; Jing-Ping Yuan; Ming-Jie Li; Xi-Yan Zhan
Journal:  World J Gastroenterol       Date:  2008-05-14       Impact factor: 5.742

Review 9.  Role of leptin and adiponectin in insulin resistance.

Authors:  Amita Yadav; Megha A Kataria; Vandana Saini; Anil Yadav
Journal:  Clin Chim Acta       Date:  2012-12-22       Impact factor: 3.786

Review 10.  Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.

Authors:  Sandra Milić; Davorka Lulić; Davor Štimac
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

View more
  2 in total

Review 1.  Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: A promising drug Potentilla discolor Bunge.

Authors:  Longshan Ji; Qian Li; Yong He; Xin Zhang; Zhenhua Zhou; Yating Gao; Miao Fang; Zhuo Yu; Robim M Rodrigues; Yueqiu Gao; Man Li
Journal:  Acta Pharm Sin B       Date:  2022-05-11       Impact factor: 14.903

2.  A network pharmacology-based approach to explore the effects of Chaihu Shugan powder on a non-alcoholic fatty liver rat model through nuclear receptors.

Authors:  Huan Nie; Yuanjun Deng; Chuiyang Zheng; Maoxing Pan; Jiqian Xie; Yupei Zhang; Qinhe Yang
Journal:  J Cell Mol Med       Date:  2020-03-18       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.